CDKN2A and acute lymphoblastic leukemia: Previous reports revealed frequent biallelic loss of CDKN2A in samples from T-ALL patients [50, 51], which suggested that there is an association between higher in vitro BTZ sensitivity of T-ALL and frequent biallelic loss of CDKN2A. In contrast, Szczepanek et al [49] reported that T-ALL samples were significantly more resistant to most of the chemotherapeutic agents in vitro than BCP-ALL samples.